Fiscal quarter ended June 2020
- supplementary financial summary -
August 4, 2020
Asahi Kasei Corporation
Contents
1. Consolidated results for fiscal quarter ended June 2020
8 Summary of financial results
9 Statements of income
- Balance sheets
- Cash flows
- Sales and operating income increase/decrease by segment
2. Forecast for first half fiscal 2020
- Consolidated operating performance forecast
- Sales and operating income forecast by segment
3. Appendix
17-18 Sales and operating income increase/decrease by business category
19-20 Sales and operating income forecast for first half by business category
- Overseas sales by business category
- Extraordinary income and loss
23-31 Overview of results by segment
32-33 Quarterly sales and operating income by segment
Disclaimer | |
The forecasts and estimates shown in this document are dependent on a variety of assumptions and | |
economic conditions. Plans and figures depicting the future do not imply a guarantee of actual outcomes. | 2 |
Focus of Q1 2020 results
- Operating income in Material decreased as an effect of global economic slowdown resulting from novel coronavirus pandemic, while operating income in Homes and Health Care increased.
- Material
Basic Materials: Operating income decreased with reduced shipment volumes, effects of lower market prices for petrochemical feedstocks on inventories, and deteriorated terms of trade for acrylonitrile (AN).
Performance Products: Operating income decreased as an effect of significant declines in demand among automobile-related markets and apparel-related markets.
Specialty Solutions: Operating income increased with favorable demand related to communications infrastructure and tablet PCs, while lithium-ion battery separator shipments increased firmly.
- Homes
- Operating income increased with firm performance of condominiums in real estate, and a portion of deliveries of order-built homes being postponed from the previous period due to delayed supply of components as an effect of the novel coronavirus.
- Orders for order-built homes decreased from the year-ago period due to restriction of admission to model homes to prevent the spread of novel coronavirus infection.
- Health Care
- Despite negative factors such as reduced outpatient visits and curtailed business activity due to the novel coronavirus, and amortization of goodwill related to the acquisition of Veloxis Pharmaceuticals Inc., operating income increased with shipment growth for ventilators and virus removal filters as an effect of
elevated demand due to the novel coronavirus. | 3 |
Focus of Q2 2020 forecast
- Q2 operating income expected to be even with Q1 in Material, increase from Q1 in Homes and Health Care; year-on-year, decrease in Material and Homes, increase in Health Care, and decrease overall.
- Material
Recovery of demand is expected, especially with recovery of vehicle production, but operating income is expected to be even with Q1 as a portion of product shipments spill into Q3. Year-on-year decrease expected with effects of lower petrochemical feedstock prices and declines in demand among automobile-related and apparel-related markets similar to Q1.
- Homes
Firm performance in real estate such as condominiums expected, but year-on-year operating income decrease with reduced deliveries of order-built homes as measures to prevent novel coronavirus infection make construction work slower, and impact of lower orders for remodeling. Orders for order-built homes expected to recover with gradual recovery of customer visits to model homes and use of digital marketing leveraging IT.
- Health Care
Year-on-year, operating income decrease expected in Health Care business category with impact of amortization of goodwill related to Veloxis, effect of novel coronavirus, and reduced reimbursement prices in Japan, but operating income increase expected in Critical Care business category centered on increased demand for ventilators; operating income increase expected for Health Care segment overall.
4
Focus of FY 2020 full-year forecast (1)
H2 2020 and full-year forecast
- Regarding the impact of the novel coronavirus, although it remains difficult to anticipate the spread of infections, economic policies, and recovery of markets in various countries, it is believed that the general trend for recovery of economic activity with measures to prevent infection will continue. Due to obscurity of the market environment outlook, the H2 and full- year forecasts for Material, having a broad scope of business activity, are determined in a range, as are the overall consolidated operating income forecasts.
- Operating income change from H1 to H2
- Material
- Operating income increase expected with improved automobile-related demand due to recovery of vehicle production, and recovery of demand and improved terms of trade for petrochemical products such as AN.
- Homes
- Slight operating income increase expected with gradual easing of restrictions to prevent novel coronavirus infection.
- Orders for order-built homes expected to recover with gradual recovery of customer visits to model homes and use of digital marketing leveraging IT.
- Health Care
- Operating income decrease expected as ventilator demand subsides and due to tendency for
Health Care business category fixed costs to occur in H2. | 5 |
Focus of FY 2020 full-year forecast (2)
H2 2020 and full-year forecast (continued)
- Full-yearforecast (net sales, operating income, year-on-year change)
- Material
Net sales decline by around 15% and operating income decline by around 50% with significant impact from novel coronavirus. - Homes
Net sales decline by around 5% and operating income decline by around 30%. - Health Care
Net sales growth by over 15% with contribution from acquired businesses and operating income growth by around 25%.
Together with curtailment of corporate expenses, overall operating income expected to decrease by around 30% to ¥120-130 billion. While the severe operating environment and uncertainty about the outlook persist, efforts will be made to improve performance by curtailing fixed costs, reducing inventories, and making swift and appropriate management decisions according to changes in the environment.
Shareholder returns
- Basic policy for stable dividends and continuously increased dividends remains unchanged.
- Interim dividends to be determined based on H1 results and full-year forecast after Q2, annual dividends to be determined based on full-year results and ascertaining effect of novel
coronavirus on the subsequent fiscal year. | 6 |
1. Consolidated results for fiscal
quarter ended June 2020
7
Summary of financial results
Q1 2019 | Q1 2020 | |
Net sales | 502.1 | 455.2 |
Operating income | 41.3 | 30.1 |
Ordinary income | 44.0 | 30.2 |
Net income attributable to owners of the parent | 24.4 | 13.6 |
¥/US$ exchange rate (market average) | 110 | 108 |
¥/€ exchange rate (market average) | 123 | 118 |
(¥ billion)
Increase % change (decrease)
(46.9) -9.3%
(11.2) -27.2%
(13.7) -31.3%
(10.8) -44.3%
(2)
(5)
8
Statements of income
(¥ billion)
Q1 2019 | Q1 2020 | Increase | % change | ||||
% of sales | % of sales | (decrease) | |||||
Net sales | 502.1 | 100.0% | 455.2 | 100.0% | (46.9) | -9.3% | |
Cost of sales | 339.4 | 67.6% | 305.3 | 67.1% | (34.1) | -10.0% | |
Gross profit | 162.7 | 32.4% | 149.9 | 32.9% | (12.8) | -7.9% | |
Selling, general and administrative expenses | 121.4 | 24.2% | 119.8 | 26.3% | (1.6) | -1.3% | |
Operating income | 41.3 | 8.2% | 30.1 | 6.6% | (11.2) | -27.2% | |
Net non-operating income (expenses) | 2.6 | 0.1 | (2.5) | ||||
of which, | |||||||
net financing income (expense) | 1.7 | 1.3 | (0.3) | ||||
net equity in earnings (losses) of affiliates | 2.2 | (0.1) | (2.3) | ||||
foreign exchange gains (loss) | (0.9) | (0.4) | 0.5 | ||||
Ordinary income | 44.0 | 8.8% | 30.2 | 6.6% | (13.7) | -31.3% | |
Net extraordinary income (loss) | (0.2) | (4.8) | (4.5) | ||||
Income before income taxes | 43.8 | 8.7% | 25.5 | 5.6% | (18.3) | -41.8% | |
Income taxes | 18.8 | 11.2 | (7.7) | ||||
Net income attributable to non-controlling interests | 0.5 | 0.7 | 0.2 | ||||
Net income attributable to owners of the parent | 24.4 | 4.9% | 13.6 | 3.0% | (10.8) | -44.3% |
9
Balance sheets
(¥ billion)
Current assets
Cash and deposits
Notes and accounts receivable-trade Inventories
Other current assets
Noncurrent assets
Property, plant and equipment Intangible assets1 Investments and other assets1
Total assets | |
1 | |
Goodwill | |
Interest-bearing debt | 2 |
D/E ratio |
At end of | At end of | Increase | At end of | At end of | Increase | ||||
Mar. 2020 | Jun. 2020 | (decrease) | Mar. 2020 | Jun. 2020 | (decrease) | ||||
1,107.4 | 1,070.9 | (36.5) | Liabilities | 1,438.8 | 1,409.0 | (29.8) | |||
208.0 | 210.1 | 2.1 | Current liabilities | 842.5 | 689.1 | (153.4) | |||
331.0 | 278.5 | (52.5) | 2 | 596.3 | 719.9 | 123.6 | |||
Noncurrent liabilities | |||||||||
477.8 | 497.1 | 19.3 | Net assets | 1,383.5 | 1,379.1 | (4.4) | |||
90.6 | 85.1 | (5.5) | Shareholders' equity | 1,302.8 | 1,294.0 | (8.8) | |||
1,714.8 | 1,717.2 | 2.4 | Capital stock | 103.4 | 103.4 | - | |||
653.7 | 664.7 | 11.1 | Capital surplus | 79.6 | 79.7 | 0.0 | |||
715.2 | 696.4 | (18.9) | Retained earnings | 1,125.7 | 1,116.9 | (8.8) | |||
345.9 | 356.1 | 10.2 | Treasury stock | (6.0) | (6.0) | (0.0) | |||
Accumulated other | 56.5 | 61.0 | 4.5 | ||||||
comprehensive income | |||||||||
Noncurrent liabilities | 24.1 | 24.1 | (0.0) | ||||||
2,822.3 | 2,788.1 | (34.2) | |||||||
Total liabilities and net assets | 2,822.3 | 2,788.1 | (34.2) | ||||||
365.7 | |||||||||
355.5 | |||||||||
(10.2) | |||||||||
703.8 | 710.8 | 7.0 | |||||||
0.52 | 0.52 | 0.01 |
1 Figures at the end of March 2020 retroactively revised reflecting PPA (purchase price allocation) results completed in Q1 2020 related to Veloxis Pharmaceuticals Inc. acquired on March 3, 2020 (CET).
Before revision : goodwill ¥149.1 billion, investments and other assets ¥5.5 billion
After revision : goodwill ¥45.2 billion, intangible assets ¥133.6 billion, noncurrent liabilities ¥24.3 billion
2 Excluding lease obligations. | 10 |
Cash flows
(¥ billion) | ||
Q1 2019 | Q1 2020 | |
a. Net cash provided by (used in) operating activities | 15.9 | 50.1 |
b. Net cash provided by (used in) investing activities | (16.4) | (32.8) |
c. Free cash flows [a+b] | (0.5) | 17.3 |
d. Net cash provided by (used in) financing activities | (5.3) | (16.4) |
e. Effect of exchange rate change on cash and cash equivalents | (4.3) | (0.5) |
f. Net increase (decrease) in cash and cash equivalents [c+d+e] | (10.1) | 0.3 |
g. Cash and cash equivalents at beginning of period | 180.5 | 204.8 |
h. Increase in cash and cash equivalents resulting from | 0.1 | 1.7 |
changes in scope of consolidation | ||
i. Cash and cash equivalents at end of period [f+g+h] | 170.5 | 206.8 |
11
Sales and operating income increase/decrease by segment
(¥ billion)
Increase (decrease) due to: | ||||||||||
Net | ||||||||||
of which, | ||||||||||
Q1 2019 | Q1 2020 | increase | % change | Sales | Sales | |||||
due to | Others | |||||||||
(decrease) | volume | prices | ||||||||
foreign | ||||||||||
exchange | ||||||||||
Material | Sales | 271.4 | 204.7 | (66.7) | -24.6% | (46.6) | (3.9) | |||
Operating | 25.9 | 8.9 | (17.0) | -65.7% | (16.1) | (16.2) | (1.4) | 15.3 | ||
income | ||||||||||
Homes | Sales | 144.6 | 150.9 | 6.3 | +4.4% | 0.4 | 7.0 | |||
Operating | 9.9 | 10.8 | 0.8 | +8.4% | (0.9) | (1.0) | - | 2.8 | ||
income | ||||||||||
Health Care1 | Sales | 82.7 | 95.7 | 13.0 | +15.7% | 8.5 | 4.7 | |||
Operating | 12.6 | 15.5 | 2.9 | +22.9% | 3.9 | (0.2) | (0.0) | (0.8) | ||
income | ||||||||||
Others | Sales | 3.5 | 3.9 | 0.4 | +11.7% | 0.4 | - | |||
Operating | 0.3 | 0.7 | 0.4 | - | 0.3 | - | - | 0.1 | ||
income | ||||||||||
Corporate expenses | Operating | (7.4) | (5.8) | 1.6 | - | - | - | - | 1.6 | |
and eliminations | income | |||||||||
Consolidated | Sales | 502.1 | 455.2 | (46.9) | -9.3% | (37.3) | 7.7 | |||
Operating | 41.3 | 30.1 | (11.2) | -27.2% | (12.8) | (17.4) | (1.4) | 18.9 | ||
income | ||||||||||
1 Results of Veloxis Pharmaceuticals Inc., acquired on March 3, 2020 (CET), are included in Health Care segment from Q1 2020.
12
2. Forecast for first half fiscal 2020
13
Consolidated operating performance forecast
FY 2019 | FY 2020 forecast | |||||
H1 | H1 | |||||
Q1 | Q2 | Q1 | Q2 | |||
a | b | |||||
Net sales | 502.1 | 566.6 | 1,068.6 | 455.2 | 523.8 | 979.0 |
Operating income | 41.3 | 60.4 | 101.7 | 30.1 | 35.9 | 66.0 |
Ordinary income | 44.0 | 61.3 | 105.3 | 30.2 | 36.3 | 66.5 |
Net income attributable to | 24.4 | 53.5 | 77.9 | 13.6 | 19.4 | 33.0 |
owners of the parent | ||||||
¥/US$ exchange rate | 110 | 107 | 109 | 108 | 105 | 106 |
(market average) | ||||||
¥/€ exchange rate | 123 | 119 | 121 | 118 | 120 | 119 |
(market average) | ||||||
(¥ billion)
Increase
(decrease) % change b-a
(89.6) -8.4%
(35.7) -35.1%
(38.8) -36.8%
(44.9) -57.6%
(2)
(2)
14
Sales and operating income forecast by segment
Sales | (¥ billion) | ||||||||
FY 2019 | FY 2020 forecast | Net | |||||||
H1 | H1 | Increase | % change | ||||||
Q2 | |||||||||
Q1 | Q2 | Q1 | (decrease) | ||||||
a | forecast | b | |||||||
b-a | |||||||||
Material | 271.4 | 288.9 | 560.2 | 204.7 | 227.3 | 432.0 | (128.2) | -22.9% | |
Homes | 144.6 | 188.9 | 333.4 | 150.9 | 179.1 | 330.0 | (3.4) | -1.0% | |
Health Care1 | 82.7 | 84.9 | 167.6 | 95.7 | 113.3 | 209.0 | 41.4 | +24.7% | |
Others | 3.5 | 3.9 | 7.4 | 3.9 | 4.1 | 8.0 | 0.6 | +8.3% | |
Consolidated | 502.1 | 566.6 | 1,068.6 | 455.2 | 523.8 | 979.0 | (89.6) | -8.4% | |
Operating income | |||||||||
FY 2019 | FY 2020 forecast | Net | |||||||
H1 | H1 | Increase | % change | ||||||
Q2 | |||||||||
Q1 | Q2 | Q1 | (decrease) | ||||||
a | forecast | b | |||||||
b-a | |||||||||
Material | 25.9 | 31.0 | 56.9 | 8.9 | 9.1 | 18.0 | (38.9) | -68.3% | |
Homes | 9.9 | 22.8 | 32.7 | 10.8 | 13.2 | 24.0 | (8.7) | -26.6% | |
Health Care1 | 12.6 | 13.3 | 25.9 | 15.5 | 20.0 | 35.5 | 9.6 | +37.0% | |
Others | 0.3 | 0.8 | 1.1 | 0.7 | 0.3 | 1.0 | (0.1) | -5.9% | |
Corporate expenses | (7.4) | (7.5) | (14.9) | (5.8) | (6.7) | (12.5) | 2.4 | - | |
and eliminations | |||||||||
Consolidated | 41.3 | 60.4 | 101.7 | 30.1 | 35.9 | 66.0 | (35.7) | -35.1% | |
1 Results of Veloxis Pharmaceuticals Inc., acquired on March 3, 2020 (CET), are included in Health Care segment from Q1 2020. | 15 |
3. Appendix
16
Sales and operating income increase/decrease by business category1 (i)
(¥ billion)
Increase (decrease) due to: | |||||||
Net | |||||||
of which, | |||||||
Q1 2019 | Q1 2020 | increase % change | Sales | Sales | due to | Others | |
(decrease) | volume | prices | foreign | ||||
exchange | |||||||
Sales2 | 81.1 | 59.8 | (21.3) | -26.2% | (8.8) | (0.8) | ||
Basic Materials | Operating | (11.6) | (0.2) | |||||
8.8 | (1.7) | (10.4) | -119.2% | (3.8) | 5.0 | |||
income | ||||||||
Sales2 | 108.6 | 67.9 | (40.7) | -37.5% | (37.6) | (0.9) | ||
Performance Products | Operating | (2.1) | (0.4) | |||||
10.4 | 1.4 | (9.0) | -86.7% | (13.1) | 6.2 | |||
income | ||||||||
Sales2 | 71.3 | 70.3 | (1.0) | -1.5% | 1.1 | 0.3 | ||
Specialty Solutions | Operating | (2.4) | (0.8) | |||||
5.4 | 7.8 | 2.4 | +43.6% | 0.8 | 4.0 | |||
income | ||||||||
Sales2 | 10.4 | 6.7 | (3.7) | -36.0% | (1.2) | (2.5) | ||
Others in Material | Operating | - | - | |||||
1.3 | 1.4 | 0.1 | +9.4% | (0.0) | 0.1 | |||
income | ||||||||
Sales | 130.6 | 139.1 | 8.5 | +6.5% | 2.6 | 7.0 | ||
Homes | Operating | (1.2) | - | |||||
8.8 | 9.8 | 1.0 | +11.6% | (0.3) | 2.5 | |||
income | ||||||||
Sales | 14.0 | 11.9 | (2.1) | -15.3% | (2.3) | - | ||
Construction Materials | Operating | 0.2 | - | |||||
1.3 | 1.1 | (0.2) | -15.0% | (0.6) | 0.3 | |||
income | ||||||||
- Figures for operating income by business category include intrasegment transactions which are eliminated from the segment totals.
- Beginning with FY 2020, method of consolidation adjustment in Material segment is changed. FY 2019 sales results are recalculated in
accordance with the change. | 17 |
Sales and operating income increase/decrease by business category1 (ii)
(¥ billion)
Increase (decrease) due to: | ||||||||||
Net | ||||||||||
of which, | ||||||||||
Q1 2019 | Q1 2020 | increase | % change | Sales | Sales | |||||
due to | Others | |||||||||
(decrease) | ||||||||||
volume | prices | |||||||||
foreign | ||||||||||
exchange | ||||||||||
Health Care2 | Sales | 34.3 | 36.5 | 2.2 | +6.5% | (0.2) | 3.0 | |||
Operating | 6.8 | 5.7 | (1.0) | -15.4% | (0.1) | (0.5) | (0.0) | (0.4) | ||
income | ||||||||||
Sales | 48.4 | 59.2 | 10.8 | +22.3% | 8.8 | 1.7 | ||||
Critical Care | Operating | 5.9 | 9.8 | 3.9 | +67.3% | 4.0 | 0.3 | (0.0) | (0.4) | |
income | ||||||||||
Sales | 3.5 | 3.9 | 0.4 | +11.7% | 0.4 | - | ||||
Others | Operating | 0.3 | 0.7 | 0.4 | - | 0.3 | - | - | 0.1 | |
income | ||||||||||
Corporate expenses | Operating | (7.4) | (5.8) | 1.6 | - | - | - | - | 1.6 | |
and eliminations | income | |||||||||
Sales | 502.1 | 455.2 | (46.9) | -9.3% | (37.3) | 7.7 | ||||
Consolidated | Operating | 41.3 | 30.1 | (11.2) | -27.2% | (12.8) | (17.4) | (1.4) | 18.9 | |
income | ||||||||||
- Figures for operating income by business category include intrasegment transactions which are eliminated from the segment totals.
- Results of Veloxis Pharmaceuticals Inc., acquired on March 3, 2020 (CET), are included in Health Care business category from Q1 2020.
18
Sales forecast for first half by business category
(¥ billion) | ||||||||||
FY 2019 | FY 2020 forecast | Increase | ||||||||
H1 | H1 | (decrease) | % change | |||||||
Q1 | Q2 | a | Q1 | Q2 | b | b-a | ||||
Basic Materials1 | 81.1 | 85.2 | 166.3 | 59.8 | 59.2 | 119.0 | (47.3) | -28.4% | ||
Performance Products1 | 108.6 | 109.4 | 217.9 | 67.9 | 89.1 | 157.0 | (60.9) | -28.0% | ||
Specialty Solutions1 | 71.3 | 84.8 | 156.1 | 70.3 | 70.7 | 141.0 | (15.1) | -9.7% | ||
Others in Material1 | 10.4 | 9.5 | 19.9 | 6.7 | 8.3 | 15.0 | (4.9) | -24.6% | ||
Homes | 130.6 | 174.3 | 304.9 | 139.1 | 166.9 | 306.0 | 1.1 | +0.4% | ||
Construction Materials | 14.0 | 14.5 | 28.6 | 11.9 | 12.1 | 24.0 | (4.6) | -16.0% | ||
Health Care2 | 34.3 | 35.8 | 70.1 | 36.5 | 39.5 | 76.0 | 5.9 | +8.4% | ||
Critical Care | 48.4 | 49.1 | 97.5 | 59.2 | 73.8 | 133.0 | 35.5 | +36.4% | ||
Others | 3.5 | 3.9 | 7.4 | 3.9 | 4.1 | 8.0 | 0.6 | +8.3% | ||
Consolidated | 502.1 | 566.6 | 1,068.6 | 455.2 | 523.8 | 979.0 | (89.6) | -8.4% | ||
- Beginning with FY 2020, method of consolidation adjustment in Material segment is changed. FY 2019 sales results are recalculated in accordance with the change.
- Results of Veloxis Pharmaceuticals Inc., acquired on March 3, 2020 (CET), are included in Health Care business category from Q1 2020.
19
Operating income forecast for first half by business category1
(¥ billion) | ||||||||
FY 2019 | FY 2020 | Increase | ||||||
H1 | H1 | |||||||
(decrease) | % change | |||||||
Q1 | Q2 | Q1 | Q2 | |||||
a | b | b-a | ||||||
Basic Materials | 8.8 | 11.3 | 20.1 | (1.7) | 1.2 | (0.5) | (20.6) | -102.5% |
Performance Products | 10.4 | 10.2 | 20.7 | 1.4 | 3.1 | 4.5 | (16.2) | -78.2% |
Specialty Solutions | 5.4 | 9.5 | 14.9 | 7.8 | 4.7 | 12.5 | (2.4) | -16.4% |
Others in Material | 1.3 | (0.1) | 1.2 | 1.4 | 0.1 | 1.5 | 0.3 | +27.7% |
Homes | 8.8 | 21.3 | 30.1 | 9.8 | 12.7 | 22.5 | (7.6) | -25.2% |
Construction Materials | 1.3 | 1.5 | 2.7 | 1.1 | 0.4 | 1.5 | (1.2) | -45.2% |
Health Care2 | 6.8 | 7.2 | 14.0 | 5.7 | 3.8 | 9.5 | (4.5) | -32.1% |
Critical Care | 5.9 | 6.1 | 11.9 | 9.8 | 16.2 | 26.0 | 14.1 | +118.2% |
Others | 0.3 | 0.8 | 1.1 | 0.7 | 0.3 | 1.0 | (0.1) | -5.9% |
Corporate expenses | (7.4) | (7.5) | (14.9) | (5.8) | (6.7) | (12.5) | 2.4 | - |
and eliminations | ||||||||
Consolidated | 41.3 | 60.4 | 101.7 | 30.1 | 35.9 | 66.0 | (35.7) | -35.1% |
- Figures for operating income by business category include intrasegment transactions which are eliminated from the segment totals.
- Results of Veloxis Pharmaceuticals Inc., acquired on March 3, 2020 (CET), are included in Health Care business category from Q1 2020.
20
Overseas sales by business category
(¥ billion)
Q1 2019 | Q1 2020 | |||||||
Overseas | Overseas | Increase | % change | |||||
Total sales | % of total | Total sales | % of total | (decrease) | ||||
sales | sales | |||||||
Basic Materials1 | 81.1 | 40.8 | 50.4% | 59.8 | 25.3 | 42.3% | (15.5) | -38.1% |
Performance Products1 | 108.6 | 65.1 | 60.0% | 67.9 | 34.5 | 50.8% | (30.7) | -47.1% |
Specialty Solutions1 | 71.3 | 47.3 | 66.3% | 70.3 | 47.5 | 67.7% | 0.3 | +0.6% |
Others in Material1 | 10.4 | 0.2 | 1.5% | 6.7 | 0.3 | 4.3% | 0.1 | +88.2% |
Homes | 130.6 | 5.1 | 3.9% | 139.1 | 4.1 | 3.0% | (0.9) | -18.6% |
Construction Materials | 14.0 | - | - | 11.9 | - | - | - | - |
Health Care2 | 34.3 | 11.8 | 34.3% | 36.5 | 15.5 | 42.4% | 3.7 | +31.7% |
Critical Care | 48.4 | 47.9 | 99.0% | 59.2 | 58.8 | 99.3% | 10.9 | +22.7% |
Others | 3.5 | 0.4 | 10.8% | 3.9 | 0.4 | 10.8% | 0.0 | +11.4% |
Total | 502.1 | 218.6 | 43.5% | 455.2 | 186.4 | 40.0% | (32.1) | -14.7% |
Asia | 111.7 | 22.2% | 84.6 | 18.6% | (27.1) | -24.3% | ||
of which, sales to China | 48.1 | 9.6% | 44.6 | 9.8% | (3.6) | -7.4% | ||
The Americas | 73.5 | 14.6% | 69.2 | 15.2% | (4.2) | -5.8% | ||
Europe | 28.0 | 5.6% | 26.4 | 5.8% | (1.6) | -5.8% | ||
Other countries | 5.4 | 1.1% | 6.2 | 1.4% | 0.8 | +15.4% | ||
Sales, excluding Homes and | 357.5 | 213.5 | 59.7% | 304.2 | 182.3 | 59.9% | ||
Construction Materials |
1 Beginning with FY 2020, method of consolidation adjustment in Material segment is changed. FY 2019 sales results are recalculated in accordance with the change.
2 Results of Veloxis Pharmaceuticals Inc., acquired on March 3, 2020 (CET), are included in Health Care business category from Q1 2020. | 21 |
Extraordinary income and loss
(¥ billion) | |||||
Q1 2019 | Q1 2020 | Increase | |||
(decrease) | |||||
Gain on sales of investment securities | 0.5 | 0.0 | (0.5) | ||
Gain on sales of noncurrent assets | 0.4 | 0.1 | (0.3) | ||
Total extraordinary income | 0.9 | 0.1 | (0.8) | ||
Loss on valuation of investment securities | - | 0.0 | 0.0 | ||
Loss on disposal of noncurrent assets | 1.0 | 1.7 | 0.7 | ||
Impairment loss | 0.0 | 0.0 | (0.0) | ||
Business structure improvement expenses | 0.1 | 3.1 | 3.0 | ||
Total extraordinary loss | 1.1 | 4.8 | 3.7 | ||
Net extraordinary income (loss) | (0.2) | (4.8) | (4.5) | ||
22
Material segment (i)
(¥ billion) | |||||
Net sales | |||||
Q1 20191 | Q1 2020 | Increase | % change | ||
(decrease) | |||||
Material segment | 271.4 | 204.7 | (66.7) | -24.6% | |
Basic Materials | 81.1 | 59.8 | (21.3) | -26.2% | |
Performance | 108.6 | 67.9 | (40.7) | -37.5% | |
Products | |||||
Specialty | 71.3 | 70.3 | (1.0) | -1.5% | |
Solutions | |||||
Others | 10.4 | 6.7 | (3.7) | -36.0% | |
Operating income2 | |||||
Q1 2019 | Q1 2020 | Increase | % change | ||
(decrease) | |||||
Material segment | 25.9 | 8.9 | (17.0) | -65.7% | |
Basic Materials | 8.8 | -1.7 | (10.4) | -119.2% | |
Performance | 10.4 | 1.4 | (9.0) | -86.7% | |
Products | |||||
Specialty | 5.4 | 7.8 | 2.4 | +43.6% | |
Solutions | |||||
Others | 1.3 | 1.4 | 0.1 | +9.4% | |
Basic Materials
Operating income decrease:
(-) Deteriorated terms of trade and decreased shipments of acrylonitrile
(-) Inventory valuation loss by the gross average method due to decreased prices for feedstock prices such as naphtha
1 Beginning with FY 2020, method of consolidation adjustment in Material segment is changed. FY 2019 sales results are recalculated in accordance with the change.
2 Figures for operating income by business category include intrasegment transactions which are eliminated from the segment totals | 23 |
Material segment (ii)
Performance Products
Operating income decrease:
- Improved terms of trade due to decreased prices for feedstock such as naphtha
(-) Decreased shipments of automobile-related products
(-) Decreased shipments of fiber products for apparel applications
Highlights
- May, decision to close spunbond nonwoven fabric plant in Nobeoka, Miyazaki
Specialty Solutions
Operating income increase:
- Increased shipments of Li-ion battery separator
- Increased shipments of electronic materials for communications infrastructure and tablet PCs
(-) Decreased shipments of automobile-related products
24
Homes segment (i)
(¥ billion)
Net sales | ||||||
Q1 2019 | Q1 2020 | Increase | % change | |||
(decrease) | ||||||
Homes segment | 144.6 | 150.9 | 6.3 | +4.4% | ||
Homes | 130.6 | 139.1 | 8.5 | +6.5% | ||
Order-built homes, etc. | 79.5 | 80.7 | 1.2 | +1.5% | ||
(Asahi Kasei Homes) | ||||||
Real estate | 31.7 | 41.5 | 9.8 | +30.8% | ||
(Asahi Kasei Realty & Residence) | ||||||
Remodeling | 13.7 | 12.0 | (1.6) | -12.0% | ||
(Asahi Kasei Reform) | ||||||
Other housing-related, etc. | 5.6 | 4.8 | (0.8) | -15.0% | ||
Construction Materials | 14.0 | 11.9 | (2.1) | -15.3% | ||
Operating income1 | ||||||
Q1 2019 | Q1 2020 | Increase | % change | |||
(decrease) | ||||||
Homes segment | 9.9 | 10.8 | 0.8 | +8.4% | ||
Homes | 8.8 | 9.8 | 1.0 | +11.6% | ||
Order-built homes, etc. | 3.7 | 3.6 | (0.1) | -2.9% | ||
(Asahi Kasei Homes) | ||||||
Real estate | ||||||
3.6 | 5.2 | 1.5 | +42.4% | |||
(Asahi Kasei Realty & Residence) | ||||||
Remodeling | 1.3 | 1.0 | (0.2) | -17.8% | ||
(Asahi Kasei Reform) | ||||||
Other housing-related, etc. | 0.2 | 0.0 | (0.2) | -90.7% | ||
Construction Materials | 1.3 | 1.1 | (0.2) | -15.0% | ||
Operating income increase:
- Firm performance of pre-built homes in real estate
- Increased deliveries of order-built homes
(-) Decreased number of remodeling works
Home order trend
Year-on-year 47.8% decrease in value of new orders for order-built homes due to restriction of admission to model homes.
1 Figures for operating income by business category include intrasegment transactions which are eliminated from the segment totals.
25
Homes segment (ii)
(¥ billion, % indicates year-on-year comparison)
Value of new orders | Sales of order-built | Sales of real estate1 | Sales of | Other | Consolidated | Order | ||||||||||
during the term | homes, etc. | Pre-built | Rental | Other | Total | remodeling | sales2 | backlog | ||||||||
homes | housing | |||||||||||||||
FY16 | H1 | 206.6 | (-4.9%) | 183.5 | (-0.1%) | 11.8 | 41.2 | 1.8 | 54.8 | 27.0 | (0.5) | 264.8 | (+2.6%) | 538.8 | ||
H2 | 194.3 | (+6.1%) | 220.8 | (-3.1%) | 9.5 | 43.5 | 1.6 | 54.6 | 29.1 | 0.8 | 305.3 | (-6.1%) | 515.8 | |||
annual | 400.9 | (+0.1%) | 404.3 | (-1.8%) | 21.3 | 84.7 | 3.4 | 109.4 | 56.1 | 0.4 | 570.2 | (-2.2%) | ||||
FY17 | H1 | 193.1 | (-6.5%) | 182.7 | (-0.4%) | 12.0 | 45.3 | 1.6 | 59.0 | 26.8 | 0.1 | 269.6 | (+1.8%) | 528.9 | ||
H2 | 212.5 | (+9.4%) | 224.1 | (+1.5%) | 14.7 | 47.8 | 2.5 | 65.1 | 28.4 | 1.1 | 318.7 | (+4.4%) | 520.9 | |||
annual | 405.6 | (+1.2%) | 406.8 | (+0.6%) | 26.8 | 93.2 | 4.2 | 124.1 | 55.2 | 2.2 | 588.3 | (+3.2%) | ||||
FY18 | H1 | 210.1 | (+8.8%) | 175.5 | (-4.0%) | 16.8 | 49.7 | 1.6 | 68.1 | 27.2 | 1.0 | 271.8 | (+0.8%) | 557.8 | ||
H2 | 241.5 | (+13.6%) | 228.2 | (+1.8%) | 13.2 | 52.1 | 2.1 | 67.4 | 31.2 | 6.1 | 332.9 | (+4.5%) | 575.0 | |||
annual | 451.6 | (+11.3%) | 403.7 | (-0.8%) | 29.9 | 101.8 | 3.7 | 135.4 | 58.4 | 7.1 | 604.7 | (+2.8%) | ||||
FY19 | Q1 | 91.2 | (-7.0%) | 79.5 | (+15.4%) | 3.5 | 26.9 | 1.3 | 31.7 | 13.7 | 5.6 | 130.6 | (+12.8%) | 590.8 | ||
Q2 | 110.7 | (-1.2%) | 117.8 | (-5.9%) | 4.0 | 27.5 | 1.0 | 32.6 | 18.3 | 5.7 | 174.4 | (+11.7%) | 589.0 | |||
H1 | 201.9 | (-3.9%) | 197.3 | (+12.4%) | 7.6 | 54.4 | 2.3 | 64.3 | 32.0 | 11.3 | 304.9 | (+12.2%) | ||||
H2 | 198.4 | (-17.8%) | 218.4 | (-4.3%) | 28.0 | 56.8 | 2.8 | 87.6 | 29.4 | 9.0 | 344.4 | (+3.4%) | 578.2 | |||
annual | 400.3 | (-11.3%) | 415.7 | (+3.0%) | 35.5 | 111.2 | 5.1 | 151.9 | 61.3 | 20.4 | 649.3 | (+7.4%) | ||||
FY20 | Q1 | 47.6 | (-47.8%) | 80.7 | (+1.5%) | 12.0 | 28.6 | 0.9 | 41.5 | 12.0 | 4.8 | 139.1 | (+6.5%) | 549.0 | ||
Q2 forcast | 88.6 | (-20.0%) | 100.3 | (-14.8%) | 18.0 | 29.9 | 1.1 | 49.0 | 13.5 | 4.2 | 166.9 | (-4.2%) | 540.4 | |||
H1 forecast | 136.2 | (-32.6%) | 181.0 | (-8.3%) | 30.0 | 58.5 | 2.0 | 90.5 | 25.5 | 9.0 | 306.0 | (+0.4%) |
- Income from maintenance service which was previously included in SG&A is included in sales beginning with FY 2019.
- Results of Erickson Framing Operations LLC and its consolidated subsidiaries, acquired on November 30, 2018 (US Eastern time), are included from Q4 2018.
26
Health Care segment (i)
(¥ billion) | |||||
Net sales | |||||
Q1 2019 | Q1 2020 | Increase | % change | ||
(decrease) | |||||
Health Care segment | 82.7 | 95.7 | 13.0 | +15.7% | |
Health Care1 | 34.3 | 36.5 | 2.2 | +6.5% | |
Critical Care | 48.4 | 59.2 | 10.8 | +22.3% | |
Operating income increase:
- Good performance of Critical Care business centering on ventilators
- Increased shipments of Planova virus removal filters
(-) Increased amortization of goodwill and intangible fixed assets due to acquisition of Veloxis
Operating income2 | |||||
Q1 2019 | Q1 2020 | Increase | % change | ||
(decrease) | |||||
Health Care segment | 12.6 | 15.5 | 2.9 | +22.9% | |
Health Care1 | 6.8 | 5.7 | (1.0) | -15.4% | |
Critical Care | 5.9 | 9.8 | 3.9 | +67.3% | |
Highlights
- May, obtainment of new drug approval in China for Flivas agent for dysuria treatment
-
June, introduction of the ZOLL AED 3 defibrillator in
US
- Results of Veloxis Pharmaceuticals Inc., acquired on March 3, 2020 (CET), are included in Health Care business category from Q1 2020.
- Figures for operating income by business category include intrasegment transactions which are eliminated from the segment totals.
27
Health Care segment (ii)
Sales of Health Care business category | (¥ billion) | ||||
FY 2019 | FY 2020 | ||||
Q1 | H1 | Q1 | |||
Pharmaceuticals1 | 15.8 | 33.3 | 18.0 | ||
Medical devices | 18.5 | 36.8 | 18.5 | ||
Total | 34.3 | 70.1 | 36.5 | ||
Main pharmaceuticals sales | |||||
FY 2019 | FY 2020 | ||||
(Sales region, monetary unit) | Q1 | H1 | Q1 | ||
Asahi Kasei Pharma | |||||
Teribone | (Japan, billion) | 6.4 | 14.4 | 6.6 | |
Recomodulin | (Japan, billion) | 2.9 | 6.1 | 2.4 | |
Kevzara | (Japan, billion) | 0.8 | 1.9 | 1.2 | |
Flivas | (Japan, billion) | 0.7 | 1.4 | 0.5 | |
Bredinin | (Japan, billion) | 0.7 | 1.4 | 0.6 | |
Elcitonin | (Japan, billion) | 0.5 | 1.1 | 0.3 | |
Reclast | (Japan, billion) | 0.4 | 0.7 | 0.3 | |
Veloxis Pharmaceuticals | |||||
Envarsus XR | (US, $ million) | 27 |
1 Results of Veloxis Pharmaceuticals Inc., acquired on March 3, 2020 (CET), are included in pharmaceuticals from Q1 2020. | 28 |
Health Care segment (iii)
Main pharmaceuticals products
Generic name | Classification | Indication | Formulation | |
Asahi Kasei Pharma | ||||
Teribone | Teriparatide acetate | Synthetic human parathyroid | Osteoporosis with high risk of fracture | Injection |
hormone (PTH) | ||||
Reclast | Zoledronic acid | Osteoporosis drug | Osteoporosis | Injection |
Recomodulin | Recombinant | Anticoagulant | Disseminated intravascular coagulation | Injection |
thrombomodulin alfa | ||||
Kevzara | Sarilumab | Interleukin-6 inhibitor | Rheumatoid arthritis not responding well to | Injection |
(rDNA origin) | conventional treatments | |||
Flivas | Naftopidil | Dysuria treatment | Benign prostatic hyperplasia | Tablet |
Elcitonin Inj. 20S | Elcatonin | Osteoporosis drug | Osteoporosis pain | Injection |
Bredinin | Mizoribine | Immunosuppressant | Rheumatoid arthritis, kidney transplantation, | Tablet |
nephrotic syndrome, lupus nephritis | ||||
Veloxis Pharmaceuticals | ||||
Envarsus XR | Tacrolimus extended- | Immunosuppressant drug | Kidney transplantation | Tablet |
release tablets | ||||
29
Health Care segment (iv) Pharmaceutical pipeline
Development | Code name, form, | Classification | Indication | Region | Origin | Remarks |
stage | generic name | |||||
AK1820, injection/ | Invasive fungal | |||||
Phase III | capsule, | Antifungal agent | Japan | Licensed | ||
infections | ||||||
isavuconazole | ||||||
ART-123, injection, | Chemotherapy- | Additional | ||||
Phase II | recombinant | Anticoagulant | induced peripheral | Japan | In-house | |
indication | ||||||
thrombomodulin alfa | neuropathy (CIPN) | |||||
Phase II | AK1830, oral | Analgesic | Pain associated with | Japan | Licensed | |
osteoarthritis | ||||||
Approved | Flivas, tablet, | Dysuria treatment | Benign prostatic | China | In-house | |
(overseas) | naftopidil | hyperplasia | ||||
Pending | HE-69, tablet, | Lupus nephritis, | Additional | |||
approval | Immunosuppressant | China | In-house | |||
mizoribine | nephrotic syndrome | indication | ||||
(overseas) | ||||||
ART-123, injection, | United | |||||
Phase III | Severe sepsis with | States, | ||||
recombinant | Anticoagulant | In-house | ||||
(overseas) | coagulopathy | Europe, | ||||
thrombomodulin alfa | ||||||
etc. | ||||||
30
Health Care segment (reference)
Financial performance of Critical Care business category in US dollars
($ million) | |||||||
FY 2019 | FY 2020 | Q1 2020 vs Q1 2019 | |||||
Q1 | H1 | H2 | Total | Q1 | Increase | % change | |
(decrease) | |||||||
Net sales | 440 | 897 | 983 | 1,880 | 550 | 110 | +24.9% |
Gross operating income before PPA1 impact | 84 | 175 | 199 | 374 | 127 | 43 | +51.0% |
Goodwill2 | (20) | (43) | (50) | (93) | (25) | (5) | |
Other intangible assets, etc.2 | (11) | (22) | (22) | (45) | (11) | 0 | |
Amortization/depreciation from PPA1 revaluation | (31) | (65) | (72) | (138) | (36) | (5) |
Consolidated operating income | 53 | 110 | 126 | 236 | 91 | 38 +70.9% |
- Purchase price allocation
- Figures shown for goodwill and other intangible assets, etc. consist of the following:
- Amortization of goodwill and other intangible assets, etc. based on Japan GAAP and US GAAP in relation to acquisition of ZOLL by Asahi Kasei in April 2012
- Amortization of goodwill and other intangible assets, etc. based on Japan GAAP in relation to acquisitions by ZOLL after April 2012
(Figures shown for gross operating income before PPA impact include amortization of intangible assets, etc. based on US GAAP in relation to acquisitions by ZOLL after April 2012.)
31
Quarterly sales by segment
(¥ billion) | ||||||||||||||||
FY 2019 | FY 2020 | FY 2020 | ||||||||||||||
Q1 | Q2 | Q3 | Q4 | Q1 | Q2 | |||||||||||
forecast | ||||||||||||||||
Material segment | 271.4 | 204.7 | 227.3 | |||||||||||||
288.9 | 275.7 | 257.3 | ||||||||||||||
Basic Materials | 1 | 81.1 | 59.8 | 59.2 | ||||||||||||
85.2 | 83.2 | 72.9 | ||||||||||||||
Performance Products | 1 | 108.6 | 109.4 | 103.6 | 99.2 | 67.9 | 89.1 | |||||||||
Specialty Solutions | 1 | 71.3 | 84.8 | 80.1 | 76.8 | 70.3 | 70.7 | |||||||||
Others | 1 | 10.4 | 9.5 | 8.7 | 8.3 | 6.7 | 8.3 | |||||||||
144.6 | 150.9 | 179.1 | ||||||||||||||
Homes segment | 188.9 | 156.3 | 214.7 | |||||||||||||
Homes | 130.6 | 139.1 | 166.9 | |||||||||||||
174.3 | 141.9 | 202.5 | ||||||||||||||
Construction Materials | 14.0 | 14.5 | 14.4 | 12.2 | 11.9 | 12.1 | ||||||||||
Health Care segment | 82.7 | 84.9 | 83.5 | 86.7 | 95.7 | 113.3 | ||||||||||
Health Care | 2 | 34.3 | 36.5 | 39.5 | ||||||||||||
35.8 | 32.3 | 30.9 | ||||||||||||||
Critical Care | 48.4 | 49.1 | 51.2 | 55.8 | 59.2 | 73.8 | ||||||||||
Others | 3.5 | 3.9 | 4.4 | 4.5 | 3.9 | 4.1 | ||||||||||
Consolidated | 502.1 | 455.2 | 523.8 | |||||||||||||
566.6 | 519.9 | 563.1 | ||||||||||||||
- Beginning with FY 2020, method of consolidation adjustment in Material segment is changed. FY 2019 sales results are recalculated in accordance with the change.
- Results of Veloxis Pharmaceuticals Inc., acquired on March 3, 2020 (CET), are included in Health Care business category from Q1 2020.
32
Quarterly operating income by segment1
(¥ billion) | ||||||||
FY 2019 | FY 2020 | FY 2020 | ||||||
Q1 | Q2 | Q3 | Q4 | Q1 | Q2 | |||
forecast | ||||||||
Material segment | 25.9 | 31.0 | 22.2 | 13.3 | 8.9 | 9.1 | ||
Basic Materials | 8.8 | 11.3 | 6.1 | 0.4 | (1.7) | 1.2 | ||
Performance Products | 10.4 | 10.2 | 7.8 | 5.3 | 1.4 | 3.1 | ||
Specialty Solutions | 5.4 | 9.5 | 8.4 | 7.1 | 7.8 | 4.7 | ||
Others | 1.3 | (0.1) | (0.0) | 0.5 | 1.4 | 0.1 | ||
Homes segment | 9.9 | 22.8 | 13.4 | 26.6 | 10.8 | 13.2 | ||
Homes | 8.8 | 21.3 | 12.1 | 25.2 | 9.8 | 12.7 | ||
Construction Materials | 1.3 | 1.5 | 1.8 | 1.1 | 1.1 | 0.4 | ||
Health Care segment | 12.6 | 13.3 | 9.9 | 7.7 | 15.5 | 20.0 | ||
Health Care2 | 6.8 | 7.2 | 3.8 | 0.1 | 5.7 | 3.8 | ||
Critical Care | 5.9 | 6.1 | 6.1 | 7.7 | 9.8 | 16.2 | ||
Others | 0.3 | 0.8 | 0.9 | 1.2 | 0.7 | 0.3 | ||
Corporate expenses | (7.4) | (7.5) | (7.8) | (11.8) | (5.8) | (6.7) | ||
and eliminations | ||||||||
Consolidated | 41.3 | 60.4 | 38.5 | 37.0 | 30.1 | 35.9 | ||
- Figures for operating income by business category include intrasegment transactions which are eliminated from the segment totals.
- Results of Veloxis Pharmaceuticals Inc., acquired on March 3, 2020 (CET), are included in Health Care business category from Q1 2020.
33
The commitment of the Asahi Kasei Group:
To do all that we can in every era to help the people of the world
make the most of life and attain fulfillment in living.
Since our founding, we have always been deeply committed to contributing to the development of society,
boldly anticipating the emergence of new needs. This is what we mean by "Creating for Tomorrow."
Attachments
- Original document
- Permalink
Disclaimer
Asahi Kasei Corporation published this content on 04 August 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 04 August 2020 03:31:03 UTC